Online citations, reference lists, and bibliographies.
← Back to Search

Clinical Advances In Molecular Biomarkers For Cancer Diagnosis And Therapy

S. Sethi, S. Ali, P. Philip, F. Sarkar
Published 2013 · Biology, Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Cancer diagnosis is currently undergoing a paradigm shift with the incorporation of molecular biomarkers as part of routine diagnostic panel. The molecular alteration ranges from those involving the DNA, RNA, microRNAs (miRNAs) and proteins. The miRNAs are recently discovered small non-coding endogenous single-stranded RNAs that critically regulates the development, invasion and metastasis of cancers. They are altered in cancers and have the potential to serve as diagnostic markers for cancer. Moreover, deregulating their activity offers novel cancer therapeutic approaches. The availability of high throughput techniques for the identification of altered cellular molecules allowed their use in cancer diagnosis. Their application to a variety of body specimens from blood to tissues has been helpful for appreciating their use in the clinical context. The development of innovative antibodies for immunohistochemical detection of proteins also assists in diagnosis and risk stratification. Overall, the novel cancer diagnostic tools have extended their application as prognostic risk factors and can be used as targets for personalized medicine.
This paper references
10.1371/journal.pone.0035309
Routine Multiplex Mutational Profiling of Melanomas Enables Enrollment in Genotype-Driven Therapeutic Trials
Christine M. Lovly (2012)
10.2217/pgs.09.172
Multiplex genotyping of CYP3A4, CYP3A5, CYP2C9 and CYP2C19 SNPs using MALDI-TOF mass spectrometry.
M. Falzoi (2010)
10.1007/s11899-013-0161-6
Are Results of Targeted Gene Sequencing Ready to Be Used for Clinical Decision Making for Patients with Acute Myelogenous Leukemia?
A. Rao (2013)
10.1158/0008-5472.CAN-10-0965
Phosphoglucose isomerase/autocrine motility factor mediates epithelial-mesenchymal transition regulated by miR-200 in breast cancer cells.
A. Ahmad (2011)
10.1097/PAT.0b013e328360b66e
Progressing the utilisation of pharmacogenetics and pharmacogenomics into clinical care.
R. Trent (2013)
10.1158/1078-0432.CCR-09-1570
KRAS Mutation in Stage III Colon Cancer and Clinical Outcome Following Intergroup Trial CALGB 89803
S. Ogino (2009)
10.1089/gtmb.2012.0510
Companion diagnostic testing for targeted cancer therapies: an overview.
Yao-Shan Fan (2013)
Flow cytometry and IG/TCR quantitative PCR for minimal residual disease quantitation in acute lymphoblastic leukemia: A French multicenter prospective study on behalf of the FRALLE
R Garand (2013)
10.1016/j.gpb.2012.08.003
Whole miRNome-wide Differential Co-expression of MicroRNAs
C. F. Stähler (2012)
10.1200/JCO.2003.01.137
Molecular oncodiagnostics: where we are and where we need to go.
E. Liu (2003)
10.1158/0008-5472.CAN-09-4598
Gemcitabine sensitivity can be induced in pancreatic cancer cells through modulation of miR-200 and miR-21 expression by curcumin or its analogue CDF.
S. Ali (2010)
10.1038/nrgastro.2011.173
Epigenetics and colorectal cancer
V. Lao (2011)
10.1586/erm.13.38
Potential epigenetic biomarkers for the diagnosis and prognosis of pancreatic ductal adenocarcinomas
J. Hinton (2013)
10.1038/bjc.2012.383
MicroRNA profiling of diagnostic needle aspirates from patients with pancreatic cancer
S. Ali (2012)
10.1371/journal.pone.0012445
Epithelial to Mesenchymal Transition Is Mechanistically Linked with Stem Cell Signatures in Prostate Cancer Cells
D. Kong (2010)
10.1038/nrclinonc.2012.137
Aspirin as adjuvant therapy for colorectal cancer—reinterpreting paradigms
W. K. Chia (2012)
10.1093/nar/gkr374
miRvestigator: web application to identify miRNAs responsible for co-regulated gene expression patterns discovered through transcriptome profiling
C. Plaisier (2011)
10.3892/or.2013.2525
microRNA detection in feces, sputum, pleural effusion and urine: novel tools for cancer screening (Review).
Yufeng Xiao (2013)
10.1371/journal.pone.0055752
Alterations in Gene Expression of Proprotein Convertases in Human Lung Cancer Have a Limited Number of Scenarios
I. Demidyuk (2013)
10.1007/s13148-011-0032-8
Long interspersed nuclear element-1 hypomethylation in cancer: biology and clinical applications
N. Kitkumthorn (2011)
Comprehensive molecular oncogenomic profiling and miRNA analysis of prostate cancer.
S. Sethi (2013)
10.4172/2157-2518.S1-005
Evolving Concept of Cancer Stem Cells: Role of Micro-RNAs and their Implications in Tumor Aggressiveness
S. Sethi (2011)
Aspirin as Adjuvant Therapy for Colorectal Cancer
A. Neugut (2009)
10.1039/c2an16154k
Rapid microRNA detection using power-free microfluidic chip: coaxial stacking effect enhances the sandwich hybridization.
Hideyuki Arata (2012)
10.1038/leu.2012.234
Flow cytometry and IG/TCR quantitative PCR for minimal residual disease quantitation in acute lymphoblastic leukemia: a French multicenter prospective study on behalf of the FRALLE, EORTC and GRAALL
R. Garand (2013)
10.1002/cncr.25588
Molecular typing of epithelial ovarian carcinomas using inflammatory markers
R. Ali-Fehmi (2011)
10.1158/1078-0432.CCR-12-0605
Mutation Profiling and Microsatellite Instability in Stage II and III Colon Cancer: An Assessment of Their Prognostic and Oxaliplatin Predictive Value
P. G. Gavin (2012)
10.1158/1078-0432.CCR-11-3210
Specific Mutations in KRAS Codons 12 and 13, and Patient Prognosis in 1075 BRAF Wild-Type Colorectal Cancers
Y. Imamura (2012)
10.1371/journal.pone.0045577
let-7b and miR-126 Are Down-Regulated in Tumor Tissue and Correlate with Microvessel Density and Survival Outcomes in Non–Small–Cell Lung Cancer
E. Jusufović (2012)
10.5858/arpa.2011-0136-OA
Design and analytic validation of BCR-ABL1 quantitative reverse transcription polymerase chain reaction assay for monitoring minimal residual disease.
L. Jennings (2012)
10.6004/JNCCN.2011.0137
NCCN Task Force report: Evaluating the clinical utility of tumor markers in oncology.
P. Febbo (2011)
10.1245/s10434-013-2910-0
Mutations in Specific Codons of the KRAS Oncogene are Associated with Variable Resistance to Neoadjuvant Chemoradiation Therapy in Patients with Rectal Adenocarcinoma
Marjun P. Duldulao (2013)
10.1038/labinvest.2013.54
Evaluating the repair of DNA derived from formalin-fixed paraffin-embedded tissues prior to genomic profiling by SNP–CGH analysis
A. Hosein (2013)
10.1186/1756-8722-5-9
Recent updates on the role of microRNAs in prostate cancer
O. Hassan (2012)
10.1016/j.clinthera.2012.06.009
Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma.
Marcus C. Ravnan (2012)
10.1134/S0026893306020178
Characterization of Russian universal kits for real-time PCR: Application to molecular oncodiagnosis
O. Y. Manzeniuk (2006)
10.1016/j.breast.2012.12.002
Additional prognostic value of the 70-gene signature (MammaPrint(®)) among breast cancer patients with 4-9 positive lymph nodes.
M. Saghatchian (2013)
Increased Ras GTPase activity is regulated by miRNAs that can be attenuated by CDF treatment in pancreatic cancer cells
S. Ali (2012)
10.1093/aje/kws226
Interdisciplinary education to integrate pathology and epidemiology: towards molecular and population-level health science.
S. Ogino (2012)
Cancer immunologyof host and tumor factors for personalized medicine
S. Ogino (2011)
10.1002/jso.23358
MiRNA‐199a‐3p: A potential circulating diagnostic biomarker for early gastric cancer
Chen Li (2013)
10.1158/1078-0432.CCR-12-2093
Molecular Pathways: Extracting Medical Knowledge from High-Throughput Genomic Data
T. Goldstein (2013)
10.1186/1471-2164-8-166
Characterization of microRNA expression profiles in normal human tissues
Yu Liang (2007)
10.1158/1535-7163.MCT-12-0232-T
Garcinol Regulates EMT and Wnt Signaling Pathways In Vitro and In Vivo, Leading to Anticancer Activity against Breast Cancer Cells
A. Ahmad (2012)
10.1593/TLO.10244
Molecular markers of epithelial-to-mesenchymal transition are associated with tumor aggressiveness in breast carcinoma.
S. Sethi (2011)
Network modeling of CDF treated pancreatic cancer cells reveals a novel c-myc-p73 dependent apoptotic mechanism.
A. Azmi (2011)
10.1371/journal.pone.0058483
Comparison of EndoPredict and Oncotype DX Test Results in Hormone Receptor Positive Invasive Breast Cancer
Z. Varga (2013)
10.1038/bcj.2012.24
Risk-based classification of leukemia by cytogenetic and multiplex molecular methods: results from a multicenter validation study
C. Gocke (2012)
10.1038/nrclinonc.2012.216
Potential biomarker for aspirin use in colorectal cancer therapy: Biological markers
R. Langley (2013)
10.1186/1471-2407-12-411
Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I
A. Mian (2012)
10.1016/j.ejca.2010.05.009
Microsatellite instability as a marker of prognosis and response to therapy: a meta-analysis of colorectal cancer survival data.
C. Guastadisegni (2010)
10.1038/nrclinonc.2012.216
Biological markers: Potential biomarker for aspirin use in colorectal cancer therapy
R. E. Langley (2013)
10.3346/jkms.2012.27.10.1155
Rapid Detection of Prognostically Significant Fusion Transcripts in Acute Leukemia Using Simplified Multiplex Reverse Transcription Polymerase Chain Reaction
Y. Cho (2012)
10.1038/nature03702
MicroRNA expression profiles classify human cancers
J. Lu (2005)
10.1371/journal.pone.0033729
Loss of Let-7 Up-Regulates EZH2 in Prostate Cancer Consistent with the Acquisition of Cancer Stem Cell Signatures That Are Attenuated by BR-DIM
D. Kong (2012)
10.1016/j.leukres.2011.12.003
RT-PCR diagnosis of recurrent rearrangements in pediatric acute lymphoblastic leukemia in Argentina.
C. Alonso (2012)
10.1700/1217.13505
Use of Luminex xMAP bead-based suspension array for detecting microRNA in NSCLC tissues and its clinical application.
Y. Wang (2012)
10.1210/jc.2012-3762
Does addition of BRAF V600E mutation testing modify sensitivity or specificity of the Afirma Gene Expression Classifier in cytologically indeterminate thyroid nodules?
R. T. Kloos (2013)
10.1177/1758834012466280
Targeted therapy and immunotherapy in advanced melanoma: an evolving paradigm
M. Khattak (2013)
10.1586/erm.13.2
Blood-based miRNAs as noninvasive diagnostic and surrogative biomarkers in colorectal cancer
T. Gall (2013)
10.1371/journal.pone.0017850
Anti-Tumor Activity of a Novel Compound-CDF Is Mediated by Regulating miR-21, miR-200, and PTEN in Pancreatic Cancer
B. Bao (2011)
10.1016/j.talanta.2013.02.028
One-step real time RT-PCR for detection of microRNAs.
Jingli Yan (2013)
10.1158/0008-5472.CAN-09-2792
miR-146a suppresses invasion of pancreatic cancer cells.
Y. Li (2010)
10.5507/BP.2010.043
Lapatinib in breast cancer - the predictive significance of HER1 (EGFR), HER2, PTEN and PIK3CA genes and lapatinib plasma level assessment.
K. Bouchalová (2010)
10.1056/NEJMoa1207756
Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival.
X. Liao (2012)
10.1002/jcp.24036
Inactivation of Ink4a/Arf leads to deregulated expression of miRNAs in K‐Ras transgenic mouse model of pancreatic cancer
S. Ali (2012)
10.1080/15287394.2012.699856
Circulating miR-155 Expression in Plasma: A Potential Biomarker for Early Diagnosis of Esophageal Cancer in Humans
Ran Liu (2012)
[Characterization of the universal Russian reagent sets for real-time PCR and its application for molecular oncodiagnostic].
O. I. Manzeniuk (2006)
10.3748/wjg.v19.i13.2011
Clinical relevance of cancer genome sequencing.
C. S. Ku (2013)
10.1016/S1470-2045(13)70110-4
Methylation of the TERT promoter and risk stratification of childhood brain tumours: an integrative genomic and molecular study.
Pedro Castelo-Branco (2013)
10.1378/chest.12-1917
Pulmonary Langerhans cell histiocytosis: profiling of multifocal tumors using next-generation sequencing identifies concordant occurrence of BRAF V600E mutations.
S. Yousem (2013)
10.1038/nrclinonc.2011.122
Cancer immunology—analysis of host and tumor factors for personalized medicine
S. Ogino (2011)
10.1371/journal.pone.0053663
A Mathematical Model for MicroRNA in Lung Cancer
Hye-Won Kang (2013)
Differentially expressed miRNAs in the plasma may provide a molecular signature for aggressive pancreatic cancer.
S. Ali (2010)
10.1056/NEJMoa1103782
Improved survival with vemurafenib in melanoma with BRAF V600E mutation.
P. Chapman (2011)
10.1002/ijc.26500
Characteristics and survival of head and neck cancer by HPV status: a cancer registry‐based study
S. Sethi (2012)
10.2217/fon.12.89
EGF receptor-targeted therapy in non-small-cell lung cancer: role of germline polymorphisms in outcome and toxicity.
E. Galvani (2012)
10.1016/j.bios.2013.02.007
A novel electrically magnetic-controllable electrochemical biosensor for the ultra sensitive and specific detection of attomolar level oral cancer-related microRNA.
Zongwen Wang (2013)



This paper is referenced by
MicroRNAs als Biomarker für Kopf-Hals-Tumore und ihre Bedeutung für eine individualisierte Strahlentherapie
I. Summerer (2016)
Automatic detection of protein degradation markers in mass spectrometry imaging
S. Herman (2016)
Biomarcadores Moleculares no Cancro da Próstata Hormono-Resistente
Juliana I. Santos (2013)
10.1016/j.pharmthera.2019.107395
Machine learning and data mining frameworks for predicting drug response in cancer: An overview and a novel in silico screening process based on association rule mining.
K. Vougas (2019)
Prediction of clinical outcomes in mantle cell lymphoma using the ACB 2000 pyrolysis 1 system
A. Inamdar (2015)
10.1016/j.talanta.2019.120669
Progress in cancer biomarkers monitoring strategies using graphene modified support materials.
S. Zaidi (2020)
10.4172/2155-9929.1000350
Cancer Immunotherapy and Personalized Medicine: Emerging Technologies and Biomarker-Based Approaches
L. Maciejko (2017)
10.1038/s41598-020-59142-9
Common and Unique microRNAs in Multiple Carcinomas Regulate Similar Network of Pathways to Mediate Cancer Progression
Divya Niveditha (2020)
10.1002/jcp.28417
Long noncoding RNAs biomarker‐based cancer assessment
Mohammad Sarfi (2019)
10.19080/AIBM.2017.06.555688
miRNA: An Overview of its Role in Cancer Research and Diagnosis
Girish K. Goswami (2017)
10.3389/fonc.2019.01496
Drug Resistance Biomarkers and Their Clinical Applications in Childhood Acute Lymphoblastic Leukemia
N. Aberuyi (2019)
10.3390/cancers10040123
Innovative Diagnostic Methods for Early Prostate Cancer Detection through Urine Analysis: A Review
Carmen Bax (2018)
10.1586/14737140.2015.1095095
Drugs acting on homeostasis: challenging cancer cell adaptation
M. Moschovi (2015)
10.2174/1566524019666190308163315
The Prognostic and Clinicopathologic Characteristics of OCT4 and Lung Cancer: A Meta-Analysis.
H. Li (2019)
10.1016/j.csbj.2020.09.027
High-throughput analysis and functional interpretation of extracellular vesicle content in hematological malignancies
Ilaria Tanasi (2020)
10.1016/J.JAAP.2016.02.019
Prediction of clinical outcomes using the pyrolysis, gas chromatography, and differential mobility spectrometry (Py-GC-DMS) system
A. Inamdar (2016)
10.1002/mgg3.1161
Comprehensive analysis of prognosis‐related methylated sites in breast carcinoma
J. Li (2020)
10.1155/2014/685396
Anaplastic Thyroid Carcinoma: Current Treatments and Potential New Therapeutic Options with Emphasis on TfR1/CD71
R. Parenti (2014)
10.3892/ol.2018.8874
miR-224/miR-141 ratio as a novel diagnostic biomarker in renal cell carcinoma
X. Chen (2018)
10.1039/c7lc00277g
Plasmonic nanohole array biosensor for label-free and real-time analysis of live cell secretion.
X. Li (2017)
10.1007/978-981-13-5877-7_16
Exploring Potential of RPPA Technique in Oral Cancer Biomarker Discovery Research
N. Singh (2019)
10.18632/ONCOTARGET.1936
Expression of stemness genes in primary breast cancer tissues: the role of SOX2 as a prognostic marker for detection of early recurrence
Mauro Finicelli (2014)
10.1371/journal.pone.0094855
MicroRNA-143 Targets Syndecan-1 to Repress Cell Growth in Melanoma
R. Li (2014)
10.1002/cyto.a.23944
Effects of Flow‐Induced Microfluidic Chip Wall Deformation on Imaging Flow Cytometry
Y. Yalikun (2019)
10.1039/C5RA01726B
Recent trends in electrochemical microRNA biosensors for early detection of cancer
Mahin Keshavarz (2015)
10.3978/j.issn.2072-1439.2013.08.08
Malignant pleural mesothelioma: current and future perspectives.
Konstantinos Porpodis (2013)
10.1093/hmg/ddw259
Cytokine genes as potential biomarkers for muscle weakness in OPMD.
Muhammad Riaz (2016)
10.1038/srep19771
Generation of 2,000 breast cancer metabolic landscapes reveals a poor prognosis group with active serotonin production
V. Leoncikas (2016)
10.1371/journal.pone.0210297
Overexpression of prostate specific membrane antigen by canine hemangiosarcoma cells provides opportunity for the molecular detection of disease burdens within hemorrhagic body cavity effusions
M. Dowling (2019)
10.1007/s13277-014-2865-1
1-butyltryptophan inhibits cell proliferation, migration, and invasion through the Akt pathway in human gastric cancer cells
T. Sun (2014)
10.1586/14737159.2014.866039
The application of monoclonal antibodies in cancer diagnosis
X. Zhang (2014)
Análisis de la expresión de marcadores tumorales en muestras de tumores humanos
Ismael Moreno Sánchez (2014)
See more
Semantic Scholar Logo Some data provided by SemanticScholar